Webinar | August 28, 2023

Industry-Leading Lentiviral Titers Through Our Optimized VirusExpress® Production Technology

Along with its many notable advantages, lentiviral vectors' attractiveness lies in their ability to be used in a wide range of cell and gene therapy indications, beyond rare diseases to serve larger patient populations. Recent regulatory approvals and clinical trial successes have led to a growing pipeline and interest in therapies using lentiviral vectors. And with that, an increased need for a robust scalable production technology that improves overall yield and quality.

In this webinar, upstream and downstream innovation scientists from MilliporeSigma will explore how they optimized their VirusExpress® production technology for lentiviral vectors to maximize titer while providing a streamlined platform to accelerate development timelines to clinical trials.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma